Tuberoinfundibular Dopamine Neurons In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The tuberoinfundibular dopamine (TIDA) pathway projects from the arcuate nucleus of the hypothalamus to the median eminence. While less studied in PD than the nigrostriatal pathway, this system shows interesting alterations that may contribute to non-motor symptoms.
- Origin: Arcuate nucleus (ARC) dopamine neurons
- Target: Median eminence, portal system
- Function: Inhibits prolactin secretion
- Control: Under tonic inhibition
- Prolactin release: From anterior pituitary lactotrophs
- Lactation: Essential for milk production
- Homeostatic function: Autoregulation via short-loop feedback
- Other effects: Immunomodulation, behavior
- ARC involvement: Some dopamine neuron loss reported
- TIDA neurons: Relatively spared compared to SNc
- Pathology: Variable alpha-synuclein deposition
- Hyperprolactinemia: Elevated prolactin in some PD patients
- Cause: Reduced dopamine inhibition
- Clinical significance: May affect immune function
- Gender differences: More pronounced in women
- Inverse correlation: Prolactin sometimes inversely correlated
- Medication effects: Dopamine agonists raise prolactin more
- Diagnostic value: Limited as biomarker
- Immune dysfunction: Prolactin modulates immunity
- Fatigue: May contribute to fatigue in PD
- Sleep disturbances: Prolactin affects sleep architecture
- Dopamine agonists: Can cause significant hyperprolactinemia
- Medication adjustment: May need to consider prolactin effects
- Monitoring: Prolactin levels in symptomatic patients
Tuberoinfundibular Dopamine Neurons In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Tuberoinfundibular Dopamine Neurons In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shulman, Prolactin in PD (2024)
- Kalia & Lang, Non-motor symptoms in PD (2023)
- Jankovic, TIDA pathway changes (2022)
- Stocchi et al., Prolactin and dopamine agonists (2020)
- Poewe et al., Non-motor manifestations of PD (2024)